Rallybio Names New Chief Medical Officer
Ticker: RLYB · Form: 8-K · Filed: Sep 17, 2024 · CIK: 1739410
| Field | Detail |
|---|---|
| Company | Rallybio Corp (RLYB) |
| Form Type | 8-K |
| Filed Date | Sep 17, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
Related Tickers: RLYB
TL;DR
Rallybio CMO out, new CMO in. New era for drug development?
AI Summary
Rallybio Corporation announced on September 16, 2024, the departure of its Chief Medical Officer, Dr. Jeffrey M. Chiodo, effective September 13, 2024. The company also announced the appointment of Dr. Sarah L. Boyce as the new Chief Medical Officer. Dr. Boyce previously served as the Senior Vice President of Clinical Development at Rallybio.
Why It Matters
A change in key leadership, especially the Chief Medical Officer, can signal shifts in the company's strategic direction or pipeline development, potentially impacting investor confidence and future research outcomes.
Risk Assessment
Risk Level: medium — Changes in key executive positions, particularly the Chief Medical Officer, can introduce uncertainty regarding the company's strategic direction and pipeline execution.
Key Players & Entities
- Rallybio Corporation (company) — Registrant
- Dr. Jeffrey M. Chiodo (person) — Departing Chief Medical Officer
- September 13, 2024 (date) — Effective date of departure
- Dr. Sarah L. Boyce (person) — Appointed Chief Medical Officer
- September 16, 2024 (date) — Date of report
FAQ
Who is the new Chief Medical Officer at Rallybio Corporation?
Dr. Sarah L. Boyce has been appointed as the new Chief Medical Officer of Rallybio Corporation.
When did Dr. Jeffrey M. Chiodo's departure become effective?
Dr. Jeffrey M. Chiodo's departure as Chief Medical Officer was effective September 13, 2024.
What was Dr. Sarah L. Boyce's previous role at Rallybio?
Before her appointment as Chief Medical Officer, Dr. Sarah L. Boyce served as the Senior Vice President of Clinical Development at Rallybio.
What is the exact date of this 8-K filing?
This 8-K filing was made as of September 17, 2024, reporting events from September 16, 2024.
What is Rallybio Corporation's primary business sector?
Rallybio Corporation operates in the Pharmaceutical Preparations sector, SIC code 2834.
Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2024-09-17 08:27:02
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share RLYB NASDAQ Global Select Mar
Filing Documents
- rlyb-20240916.htm (8-K) — 23KB
- 0001739410-24-000121.txt ( ) — 150KB
- rlyb-20240916.xsd (EX-101.SCH) — 2KB
- rlyb-20240916_lab.xml (EX-101.LAB) — 23KB
- rlyb-20240916_pre.xml (EX-101.PRE) — 13KB
- rlyb-20240916_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. RALLYBIO CORPORATION Date: September 17, 2024 By: /s/ Jonathan I. Lieber Jonathan I. Lieber Chief Financial Officer and Treasurer